Global disease prevalence: Cholangiocarcinoma (bile duct cancer) is a relatively rare malignant tumor worldwide; it has a higher incidence in Southeast Asia, is highly locally invasive, and carries a poor prognosis.
Staging-based treatment for cholangiocarcinoma
Early treatment (involving a localized, small tumor with a favorable response)
specifically surgical resection combined with adjuvant therapy—can effectively control tumor progression, and the patient's prognosis is relatively good.
Treatment for the intermediate stage (involving local spread; aiming to inhibit growth and delay progression)
employs a comprehensive approach—such as surgery combined with radiotherapy and chemotherapy—to control further tumor spread and slow the rate of disease deterioration.
Treatment for advanced disease (distant metastasis; aimed at symptom relief and survival prolongation)
primarily employs systemic therapies such as chemotherapy, targeted therapy, and others to alleviate clinical symptoms and extend patient survival as much as possible.
Why choose Fosun Health for bile duct cancer treatment
Fosun Health’s cholangiocarcinoma diagnosis and treatment services are managed by the Hepatobiliary and Pancreatic Surgery team, which possesses extensive experience in high-difficulty procedures such as radical resection for hilar cholangiocarcinoma and pancreaticoduodenectomy.The discipline leader, Professor Zhang Jihong—formerly a Chief Physician in the Department of Hepatobiliary and Pancreatic Surgery at the First Affiliated Hospital of Sun Yat-sen University—specializes in complex surgeries like radical resection for hilar cholangiocarcinoma; Chief Physician Peng Liang and Associate Chief Physician Zhang Haixiong are highly skilled in da Vinci robotic surgery and fluorescence-guided laparoscopic radical resection for cholangiocarcinoma.Leveraging a global medical network, patients have access to cutting-edge treatment options, including da Vinci robot-assisted radical resection for cholangiocarcinoma, laparoscopic minimally invasive surgery, CyberKnife M6 precision radiotherapy, targeted therapy, and immunotherapy.
For complex cases such as unresectable, locally advanced, or recurrent cholangiocarcinoma, a Multidisciplinary Team (MDT)—comprising experts from hepatopancreatobiliary surgery, medical oncology, radiology, and pathology—formulates the optimal treatment plan; a cross-border consultation mechanism provides patients with second opinions from top-tier overseas hepatobiliary tumor centers.
Fosun Health continues to introduce innovative technologies for the treatment of cholangiocarcinoma.Foshan Fosun Chancheng Hospital is equipped with Foshan’s first sixth-generation CyberKnife M6 system; offering 0.1mm precision, it delivers therapeutic outcomes comparable to surgery for patients with inoperable cholangiocarcinoma.Patients confirmed via molecular testing to harbor specific targets—such as FGFR2 fusions/rearrangements or IDH1 mutations—can receive corresponding targeted therapies.By integrating precision surgery, stereotactic radiotherapy, and targeted immunotherapy, the hospital provides personalized, comprehensive care for patients at various stages of the disease.
Cholangiocarcinoma Treatment Methods
1.Radical surgery for bile duct cancer
For patients with cholangiocarcinoma who are candidates for surgery, the choice of procedure—such as bile duct resection, liver resection, or other appropriate radical surgeries—depends on the tumor's location.
Treatment advantages:
① Direct tumor resection: For resectable lesions, the primary tumor can be removed surgically.
② Pathological staging: Surgical specimens can be used for pathological examination and lymph node assessment.
③ Personalized surgery: The surgical plan is tailored based on the tumor's location, extent, and vascular invasion.
④ Local control: For localized, resectable disease, surgery can serve as the primary curative treatment modality.
2.CyberKnife precision radiotherapy
For selected patients with unresectable, locally recurrent, or specific locally advanced cholangiocarcinoma, CyberKnife precision radiotherapy may be considered based on tumor location and the status of adjacent organs.
Treatment advantages:
① Precise localization: Formulate an individualized radiotherapy plan based on the tumor location.
② Local irradiation: Concentrates on the target lesion to control the local tumor.
③ Protection of adjacent tissues: Prioritize the control of radiation doses to surrounding normal tissues, such as the liver and gastrointestinal tract.
④ Applicable to specific situations: Can provide a treatment option for some patients unsuitable for surgery or those with local recurrence.
3.VitalBeam linear accelerator precision radiotherapy
Based on the VitalBeam linear accelerator platform, precise radiotherapy can be administered according to the location and size of the bile duct tumor and the status of adjacent organs.
Treatment advantages:
① Precision irradiation: Formulate an individualized treatment plan based on the extent of the lesion.
② Dose optimization: Optimizes the dose distribution between the target area and surrounding normal tissues.
③ Protects normal tissues: Minimizes radiation exposure to vital organs such as the liver and gastrointestinal tract as much as possible.
④ Combination therapy: May be used in combination with treatment modalities such as chemotherapy, depending on the disease stage.
4.Biliary interventional drainage
For patients with biliary obstruction, jaundice, or impaired bile drainage caused by the tumor, biliary drainage or stent placement may be performed via endoscopic or percutaneous biliary intervention to improve bile drainage and facilitate subsequent treatment.
Treatment advantages:
① Relieve obstruction: Alleviate biliary obstruction caused by the tumor.
② Symptom relief: Helps alleviate symptoms associated with biliary obstruction, such as jaundice and pruritus.
③ Improve liver function: Can improve certain markers associated with cholestasis following the restoration of biliary drainage.
④ Supports subsequent therapy: Some patients may undergo further anti-tumor treatment once their biliary condition improves.
5.Hepatic artery interventional therapy
For certain patients with intrahepatic cholangiocarcinoma or those whose primary disease burden consists of hepatic lesions, hepatic arterial interventional therapy may be evaluated based on tumor distribution and liver function.
Treatment advantages:
① Local drug delivery: Local treatment administered via tumor-feeding blood vessels.
② Targeting intrahepatic lesions: Suitable for certain patients where the liver lesion is the primary treatment target.
③ Minimally invasive interventional procedure: Treatment performed via an endovascular approach.
④ Personalized application: Select a treatment regimen based on tumor number, distribution, and liver function.
6.Particle implantation
For selected patients with unresectable cholangiocarcinoma requiring local therapy, radioactive seed implantation may be considered based on tumor location, biliary tract status, and treatment history.
7.Chemotherapy
Kills cancer cells using regimens such as gemcitabine combined with cisplatin to effectively control the rate of tumor progression; commonly used for patients with intermediate-to-advanced cholangiocarcinoma.
8.Targeted therapy
Precision targeting of specific molecular targets such as FGFR offers good efficacy and relatively mild side effects, making it suitable for patients with advanced disease.
9.Immunotherapy
Activates the body's immune system to recognize and attack cancer cells, providing a new, effective treatment option for patients with advanced bile duct cancer to improve therapeutic efficacy.
10 Comprehensive treatment
Formulate an individualized comprehensive treatment plan—combining surgery, chemoradiotherapy, and other modalities based on the patient's specific condition—to comprehensively enhance therapeutic efficacy;administer treatment.
11 Supportive care
Approaches such as nutritional support, psychological counseling, and symptom management can comprehensively improve the patient's physical condition and quality of life, as well as consolidate therapeutic efficacy.
Post-treatment care
Maintain a low-fat, high-protein diet and a regular daily routine; avoid greasy foods; attend scheduled follow-up appointments; and actively cooperate with subsequent treatments.
Post-treatment examinations
Regular abdominal CT scans, tumor marker tests, and liver function tests are required after treatment to detect changes in the condition in a timely manner.
Conclusion
Cholangiocarcinoma poses a serious threat; successful treatment hinges on early detection, diagnosis, and intervention, as well as selecting an appropriate treatment plan and adhering to follow-up care to improve quality of life.
